Prelude Therapeutics Ratios (2024-2025) | PRLD

Ratios Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025
Profitability
EBT Margin -1,145.87%-845.78%-314.12%
EBIT Margin -1,145.87%-845.78%-314.12%
EBITDA Margin -1,060.47%-721.58%-303.42%
Operating Margin -1,145.87%-845.78%-314.12%
Net Margin -1,145.87%-845.78%-314.12%
FCF Margin -911.97%-519.93%-294.08%
Efficiency
Assets Average 235.70M210.76M186.37M158.39M128.09M104.84M
Equity Average 196.50M169.35M143.94M117.32M89.51M67.19M
Invested Capital 210.73M182.28M156.43M131.46M103.18M75.84M58.53M
Leverage & Solvency
Equity Ratio 0.850.810.790.750.730.660.62
Valuation
Enterprise Value 54.36M25.39M-43.77M-67.49M-119.55M-79.06M15.88M
Market Capitalization 260.32M209.28M113.90M70.17M42.36M45.70M81.50M